Dr. Ben-Zion Weiner was Head of Global Research and Development at Teva Pharmaceutical Industries Ltd. for over three decades, and also served as a member of the Teva Executive Committee. He directly oversaw all pharmaceutical development and regulatory approval of Teva’s innovative product pipeline. Dr. Weiner was also responsible for the development of hundreds of generic products for the US, European, and other markets. Dr. Weiner has twice been awarded the Rothschild Prize for Industrial Innovation, including for the development and commercialization of Copaxone for the treatment of multiple sclerosis. Dr. Weiner has been involved in multiple pharmaceutical activities since retiring from Teva, and currently serves on the Mesoblast board of directors as an independent non-executive director. He received a BSc degree in general chemistry and biochemistry and an MSc degree in organic chemistry, graduating with distinction for both degrees from the Hebrew University, Jerusalem. He received his PhD degree in chemistry at the Hebrew University, Jerusalem, and conducted his post-doctoral research at Schering-Plough Corporation in the United States.
Dr. Chen-Walden has specialized in regulatory affairs in the pharmaceutical industry in the US and Europe. She has thirty years of regulatory experience in EMEA and in individual European countries. Since 2004, She has consulted for the European Clinical and Regulatory Consultancy in medical monitoring, quality assurance, and regulatory input for clinical studies in the fields of oncology, cardiology, diabetes, neurology, respiratory diseases, and medical devices. From 2000 to 2003, Dr. Chen-Walden was Director of International Regulatory Affairs, Covalent Group Ltd. From 1997 to 2000, she was Medical, Drug Safety, and Regulatory Director at CRC, a clinical contract research organization in France. Dr. Chen-Walden received her MD degree from the University of Tel Aviv, Israel. She has practiced medicine in Germany and France.
Dr. Bell is an adjunct clinical professor of medicine at the University of Alabama at Birmingham School of Medicine, where from 1980 to 2005 he served as a professor of medicine. The author or coauthor of more than 320 publications, he is a Fellow of the American College of Physicians, a Fellow of the Royal College of Physicians of Edinburgh, and a Fellow of the Royal College of Physicians and Surgeons of Canada. He is a member of the American Diabetes Association, and is on the editorial boards of the journals Diabetes Obesity and Metabolism and Endocrine Today. He is a graduate of Belfast Royal Academy and Queens University School of Medicine, from which he graduated with the MB, BCh, and BAO degrees.
A former chairman of the board of the American Diabetes Association, Mr. Ellingson has more than four decades of experience in drug development, with a strong emphasis on diabetes and related diseases. Mr. Ellingson is the principal of Global Diabetes Consulting, which works with several companies as well as the North Dakota State University College of Pharmacy. He was Executive Director Diabetes Care at Eli Lilly & Co. He is also a former chairman of the board of Protemix Ltd., a biotechnology company focused on proteomics and the development of molecules for diabetes and related diseases. He holds an executive MBA degree from Babson College and a BS degree in pharmacy from North Dakota State University.
Ache is a veteran of the biotech industry. He spent over 20 years at Amgen where he invented, developed, and deployed new technologies and methods for process development. In the early 90s he was involved with the development and construction of the manufacturing system for GCSF™. He went on to join the process development department, where he developed innovative purification techniques and process automation systems that helped bring to market many successful molecules. Subsequently he managed a multi-million-dollar startup collaboration to transform cell-culture process development. The project introduced a first-ever integrated robotic platform that executed fully automated cell culture experiments. Earlier in his career he designed and installed safety and control systems on offshore platforms. He obtained a BS in Mechanical Engineering at The Technion, Israel (1990).